Role of 18F-PSMA-1007 PET/CT-derived quantitative volumetric tumor parameters in cytoreductive radical prostatectomy selection for patients with low-volume metastatic hormone-sensitive prostate cancer: a retrospective study
Abstract Background Cytoreductive radical prostatectomy (cRP) has emerged as a promising therapeutic approach for low-volume metastatic hormone-sensitive prostate cancer (mHSPC), but the best candidates for cRP are still unknown. This study aims to explore the potential value of 18F-PSMA-1007 PET/CT...
Saved in:
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-02-01
|
| Series: | BMC Cancer |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12885-025-13482-9 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1823861957837455360 |
|---|---|
| author | Junjie Fan Ke Xu Zhangdong Jiang Chaosheng Gan Hao Song Guoqiang Gao Guojing Wang Qiyuan Kang Liang Luo Zhuonan Wang Dalin He XiaoYi Duan Kaijie Wu |
| author_facet | Junjie Fan Ke Xu Zhangdong Jiang Chaosheng Gan Hao Song Guoqiang Gao Guojing Wang Qiyuan Kang Liang Luo Zhuonan Wang Dalin He XiaoYi Duan Kaijie Wu |
| author_sort | Junjie Fan |
| collection | DOAJ |
| description | Abstract Background Cytoreductive radical prostatectomy (cRP) has emerged as a promising therapeutic approach for low-volume metastatic hormone-sensitive prostate cancer (mHSPC), but the best candidates for cRP are still unknown. This study aims to explore the potential value of 18F-PSMA-1007 PET/CT-derived quantitative volumetric tumor parameters in cRP treatment selection among patients with low-volume mHSPC. Methods A total of 122 patients with primary low-volume mHSPC who underwent 18F-PSMA-1007 PET/CT followed by systemic therapy alone or plus cRP were included. The whole-body PSMA-derived tumor volume (PSMA-TV) was defined as the total volume of whole-body PSMA-avid tumor lesions, and prostate PSMA-TV was defined as the volume of prostate PSMA-avid tumor lesions. Spearman’s correlation was used to analyze the relationships between whole-body PSMA-TV and clinicopathological characteristics. The primary endpoint was progression-free survival (PFS), and Cox regression analyses were performed to explore the independent predictors for PFS. Results Among 122 patients, 37 (30.32%) underwent systemic therapy plus cRP. The median and optimal cutoff values of the whole-body PSMA-TV were 71.68 cm3 (41.28–157.41 cm3) and 78.57 cm3, respectively. Whole-body PSMA-TV was positively correlated with prostate-specific antigen (PSA), and patients with nonregional lymph node (NRLN) metastases had a greater whole-body PSMA-TV (P = 0.001). Cox regression analyses revealed that cRP, lower whole-body PSMA-TV and the absence of NRLN metastases were associated with better PFS (all P < 0.05). Subgroup analyses revealed that patients with a low whole-body PSMA or no NRLN metastases had a significant improvement in PFS for cRP versus no cRP (HR: 8.26; 95% CI: 2.72–25.06, P = 0.001; HR: 2.71; 95% CI: 1.25–5.93, P = 0.018). Moreover, among patients with higher prostate PSMA-TV and prostate PSMA-TV/whole-body PSMA-TV, cRP also significantly prolonged PFS compared with those without cRP (HR: 3.49; 95% CI: 1.49–8.18, P = 0.004; HR: 8.54; 95% CI: 2.47–29.50, P = 0.013). Conclusion In management of primary low-volume mHSPC, whole-body and prostate PSMA-TV evaluations based on 18F-PSMA-1007 PET/CT could be helpful to identify the most suitable candidates for cRP. Trial registration Retrospectively registered. |
| format | Article |
| id | doaj-art-4874dbec8bc142ada2162bf50749fc54 |
| institution | Kabale University |
| issn | 1471-2407 |
| language | English |
| publishDate | 2025-02-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Cancer |
| spelling | doaj-art-4874dbec8bc142ada2162bf50749fc542025-02-09T12:41:22ZengBMCBMC Cancer1471-24072025-02-0125111110.1186/s12885-025-13482-9Role of 18F-PSMA-1007 PET/CT-derived quantitative volumetric tumor parameters in cytoreductive radical prostatectomy selection for patients with low-volume metastatic hormone-sensitive prostate cancer: a retrospective studyJunjie Fan0Ke Xu1Zhangdong Jiang2Chaosheng Gan3Hao Song4Guoqiang Gao5Guojing Wang6Qiyuan Kang7Liang Luo8Zhuonan Wang9Dalin He10XiaoYi Duan11Kaijie Wu12Department of Urology, The First Affiliated Hospital of Xi’an Jiaotong UniversityDepartment of Urology, The First Affiliated Hospital of Xi’an Jiaotong UniversityDepartment of Urology, The First Affiliated Hospital of Xi’an Jiaotong UniversityDepartment of Urology, The First Affiliated Hospital of Xi’an Jiaotong UniversityDepartment of Urology, The First Affiliated Hospital of Xi’an Jiaotong UniversityDepartment of Urology, The First Affiliated Hospital of Xi’an Jiaotong UniversityDepartment of Urology, The First Affiliated Hospital of Xi’an Jiaotong UniversityDepartment of Urology, The First Affiliated Hospital of Xi’an Jiaotong UniversityDepartment of PET/CT imaging, The First Affiliated Hospital of Xi’an Jiaotong UniversityDepartment of PET/CT imaging, The First Affiliated Hospital of Xi’an Jiaotong UniversityDepartment of Urology, The First Affiliated Hospital of Xi’an Jiaotong UniversityDepartment of PET/CT imaging, The First Affiliated Hospital of Xi’an Jiaotong UniversityDepartment of Urology, The First Affiliated Hospital of Xi’an Jiaotong UniversityAbstract Background Cytoreductive radical prostatectomy (cRP) has emerged as a promising therapeutic approach for low-volume metastatic hormone-sensitive prostate cancer (mHSPC), but the best candidates for cRP are still unknown. This study aims to explore the potential value of 18F-PSMA-1007 PET/CT-derived quantitative volumetric tumor parameters in cRP treatment selection among patients with low-volume mHSPC. Methods A total of 122 patients with primary low-volume mHSPC who underwent 18F-PSMA-1007 PET/CT followed by systemic therapy alone or plus cRP were included. The whole-body PSMA-derived tumor volume (PSMA-TV) was defined as the total volume of whole-body PSMA-avid tumor lesions, and prostate PSMA-TV was defined as the volume of prostate PSMA-avid tumor lesions. Spearman’s correlation was used to analyze the relationships between whole-body PSMA-TV and clinicopathological characteristics. The primary endpoint was progression-free survival (PFS), and Cox regression analyses were performed to explore the independent predictors for PFS. Results Among 122 patients, 37 (30.32%) underwent systemic therapy plus cRP. The median and optimal cutoff values of the whole-body PSMA-TV were 71.68 cm3 (41.28–157.41 cm3) and 78.57 cm3, respectively. Whole-body PSMA-TV was positively correlated with prostate-specific antigen (PSA), and patients with nonregional lymph node (NRLN) metastases had a greater whole-body PSMA-TV (P = 0.001). Cox regression analyses revealed that cRP, lower whole-body PSMA-TV and the absence of NRLN metastases were associated with better PFS (all P < 0.05). Subgroup analyses revealed that patients with a low whole-body PSMA or no NRLN metastases had a significant improvement in PFS for cRP versus no cRP (HR: 8.26; 95% CI: 2.72–25.06, P = 0.001; HR: 2.71; 95% CI: 1.25–5.93, P = 0.018). Moreover, among patients with higher prostate PSMA-TV and prostate PSMA-TV/whole-body PSMA-TV, cRP also significantly prolonged PFS compared with those without cRP (HR: 3.49; 95% CI: 1.49–8.18, P = 0.004; HR: 8.54; 95% CI: 2.47–29.50, P = 0.013). Conclusion In management of primary low-volume mHSPC, whole-body and prostate PSMA-TV evaluations based on 18F-PSMA-1007 PET/CT could be helpful to identify the most suitable candidates for cRP. Trial registration Retrospectively registered.https://doi.org/10.1186/s12885-025-13482-918F-PSMA-1007 PET/CTLow-volume mHSPCPSMA-TVNonregional lymph node metastasesCytoreductive radical prostatectomy |
| spellingShingle | Junjie Fan Ke Xu Zhangdong Jiang Chaosheng Gan Hao Song Guoqiang Gao Guojing Wang Qiyuan Kang Liang Luo Zhuonan Wang Dalin He XiaoYi Duan Kaijie Wu Role of 18F-PSMA-1007 PET/CT-derived quantitative volumetric tumor parameters in cytoreductive radical prostatectomy selection for patients with low-volume metastatic hormone-sensitive prostate cancer: a retrospective study BMC Cancer 18F-PSMA-1007 PET/CT Low-volume mHSPC PSMA-TV Nonregional lymph node metastases Cytoreductive radical prostatectomy |
| title | Role of 18F-PSMA-1007 PET/CT-derived quantitative volumetric tumor parameters in cytoreductive radical prostatectomy selection for patients with low-volume metastatic hormone-sensitive prostate cancer: a retrospective study |
| title_full | Role of 18F-PSMA-1007 PET/CT-derived quantitative volumetric tumor parameters in cytoreductive radical prostatectomy selection for patients with low-volume metastatic hormone-sensitive prostate cancer: a retrospective study |
| title_fullStr | Role of 18F-PSMA-1007 PET/CT-derived quantitative volumetric tumor parameters in cytoreductive radical prostatectomy selection for patients with low-volume metastatic hormone-sensitive prostate cancer: a retrospective study |
| title_full_unstemmed | Role of 18F-PSMA-1007 PET/CT-derived quantitative volumetric tumor parameters in cytoreductive radical prostatectomy selection for patients with low-volume metastatic hormone-sensitive prostate cancer: a retrospective study |
| title_short | Role of 18F-PSMA-1007 PET/CT-derived quantitative volumetric tumor parameters in cytoreductive radical prostatectomy selection for patients with low-volume metastatic hormone-sensitive prostate cancer: a retrospective study |
| title_sort | role of 18f psma 1007 pet ct derived quantitative volumetric tumor parameters in cytoreductive radical prostatectomy selection for patients with low volume metastatic hormone sensitive prostate cancer a retrospective study |
| topic | 18F-PSMA-1007 PET/CT Low-volume mHSPC PSMA-TV Nonregional lymph node metastases Cytoreductive radical prostatectomy |
| url | https://doi.org/10.1186/s12885-025-13482-9 |
| work_keys_str_mv | AT junjiefan roleof18fpsma1007petctderivedquantitativevolumetrictumorparametersincytoreductiveradicalprostatectomyselectionforpatientswithlowvolumemetastatichormonesensitiveprostatecanceraretrospectivestudy AT kexu roleof18fpsma1007petctderivedquantitativevolumetrictumorparametersincytoreductiveradicalprostatectomyselectionforpatientswithlowvolumemetastatichormonesensitiveprostatecanceraretrospectivestudy AT zhangdongjiang roleof18fpsma1007petctderivedquantitativevolumetrictumorparametersincytoreductiveradicalprostatectomyselectionforpatientswithlowvolumemetastatichormonesensitiveprostatecanceraretrospectivestudy AT chaoshenggan roleof18fpsma1007petctderivedquantitativevolumetrictumorparametersincytoreductiveradicalprostatectomyselectionforpatientswithlowvolumemetastatichormonesensitiveprostatecanceraretrospectivestudy AT haosong roleof18fpsma1007petctderivedquantitativevolumetrictumorparametersincytoreductiveradicalprostatectomyselectionforpatientswithlowvolumemetastatichormonesensitiveprostatecanceraretrospectivestudy AT guoqianggao roleof18fpsma1007petctderivedquantitativevolumetrictumorparametersincytoreductiveradicalprostatectomyselectionforpatientswithlowvolumemetastatichormonesensitiveprostatecanceraretrospectivestudy AT guojingwang roleof18fpsma1007petctderivedquantitativevolumetrictumorparametersincytoreductiveradicalprostatectomyselectionforpatientswithlowvolumemetastatichormonesensitiveprostatecanceraretrospectivestudy AT qiyuankang roleof18fpsma1007petctderivedquantitativevolumetrictumorparametersincytoreductiveradicalprostatectomyselectionforpatientswithlowvolumemetastatichormonesensitiveprostatecanceraretrospectivestudy AT liangluo roleof18fpsma1007petctderivedquantitativevolumetrictumorparametersincytoreductiveradicalprostatectomyselectionforpatientswithlowvolumemetastatichormonesensitiveprostatecanceraretrospectivestudy AT zhuonanwang roleof18fpsma1007petctderivedquantitativevolumetrictumorparametersincytoreductiveradicalprostatectomyselectionforpatientswithlowvolumemetastatichormonesensitiveprostatecanceraretrospectivestudy AT dalinhe roleof18fpsma1007petctderivedquantitativevolumetrictumorparametersincytoreductiveradicalprostatectomyselectionforpatientswithlowvolumemetastatichormonesensitiveprostatecanceraretrospectivestudy AT xiaoyiduan roleof18fpsma1007petctderivedquantitativevolumetrictumorparametersincytoreductiveradicalprostatectomyselectionforpatientswithlowvolumemetastatichormonesensitiveprostatecanceraretrospectivestudy AT kaijiewu roleof18fpsma1007petctderivedquantitativevolumetrictumorparametersincytoreductiveradicalprostatectomyselectionforpatientswithlowvolumemetastatichormonesensitiveprostatecanceraretrospectivestudy |